Zydus Lifesciences
- Advice
- Hold
Zydus Lifesciences Performance
Day Range
- Low 630.85
- High 664.95
52 Week Range
- Low 403.20
- High 668.75
- Open Price661.30
- Previous Close657.95
- Volume2333950
Start SIP in Zydus Lifesciences
Start SIPZydus Lifesciences Investment Rating
-
Master Rating:
-
Zydus Lifesciences has an operating revenue of Rs. 18,881.30 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 15% is great, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 12% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 4% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 87 which is a GOOD score indicating consistency in earnings, a RS Rating of 58 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 2,159 | 2,956 | 2,437 | 2,087 | 2,217 | 1,981 | 1,919 |
Operating Expenses Qtr Cr | 1,510 | 1,815 | 1,807 | 1,628 | 1,720 | 1,437 | 1,562 |
Operating Profit Qtr Cr | 649 | 1,141 | 773 | 459 | 679 | 544 | 458 |
Depreciation Qtr Cr | 125 | 121 | 120 | 122 | 124 | 123 | 123 |
Interest Qtr Cr | 91 | 90 | 85 | 89 | 64 | 41 | 42 |
Tax Qtr Cr | 163 | 232 | 124 | 129 | 149 | 101 | 100 |
Net Profit Qtr Cr | 805 | 781 | 491 | 256 | 451 | 332 | 247 |
Zydus Lifesciences Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 14
- Bearish Moving Average
- ___
- 2
- 20 Day
- ₹631.13
- 50 Day
- ₹619.21
- 100 Day
- ₹605.11
- 200 Day
- ₹569.13
- 20 Day
- ₹634.16
- 50 Day
- ₹609.07
- 100 Day
- ₹620.74
- 200 Day
- ₹567.01
Zydus Lifesciences Resistance and Support
Resistance | |
---|---|
First Resistance | 658.72 |
Second Resistance | 678.88 |
Third Resistance | 692.82 |
RSI | 56.10 |
MFI | 65.13 |
MACD Single Line | 9.64 |
MACD | 9.58 |
Support | |
---|---|
First Resistance | 624.62 |
Second Resistance | 610.68 |
Third Resistance | 590.52 |
Zydus Lifesciences Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 2,462,014 | 102,764,464 | 41.74 |
Week | 1,642,355 | 75,548,348 | 46 |
1 Month | 1,093,085 | 52,970,890 | 48.46 |
6 Month | 1,192,593 | 57,327,951 | 48.07 |
Zydus Lifesciences Result Highlights
Zydus Lifesciences Synopsis
NSE-Medical-Generic Drugs
Zydus Lifesciences is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 8731.60 Cr. and Equity Capital is Rs. 101.20 Cr. for the Year ended 31/03/2023. Zydus Lifesciences Ltd. is a Public Limited Listed company incorporated on 15/05/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC025878 and registration number is 025878.Market Cap | 64,634 |
Sales | 9,781 |
Shares in Float | 25.31 |
No of funds | 341 |
Yield | 0.94 |
Book Value | 4.74 |
U/D Vol ratio | 1 |
LTDebt / Equity | 28 |
Alpha | 0.16 |
Beta | 0.48 |
Zydus Lifesciences
Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
---|---|---|---|---|
Promoters | 74.98% | 74.98% | 74.98% | 74.98% |
Mutual Funds | 5.94% | 5.8% | 5.59% | 5.56% |
Insurance Companies | 6.86% | 7.43% | 7.67% | 7.87% |
Foreign Portfolio Investors | 4.85% | 4.04% | 3.42% | 2.52% |
Financial Institutions/ Banks | ||||
Individual Investors | 5.66% | 5.97% | 6.42% | 7.04% |
Others | 1.71% | 1.78% | 1.92% | 2.03% |
Zydus Lifesciences Management
Name | Designation |
---|---|
Mr. Pankaj R Patel | Chairman |
Dr. Sharvil P Patel | Managing Director |
Mr. Ganesh N Nayak | Executive Director |
Mr. Bhadresh K Shah | Independent Director |
Mr. Mukesh M Patel | Non Executive Director |
Mr. Nitin R Desai | Independent Director |
Ms. Dharmishtaben N Raval | Independent Woman Director |
Ms. Apurva S Diwanji | Independent Director |
Mrs. Upasana Konidela | Independent Woman Director |
Mr. Monappa Arun Akhil | Independent Director |
Zydus Lifesciences Forecast
Price Estimates
Zydus Lifesciences Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-11-07 | Quarterly Results | |
2023-08-11 | Quarterly Results | |
2023-05-18 | Audited Results & Final Dividend | |
2023-02-03 | Quarterly Results | |
2022-11-11 | Quarterly Results |
Date | Purpose | Remarks |
---|---|---|
2023-07-28 | FINAL | Rs.6.00 per share(600%)Final Dividend |
2022-07-29 | FINAL | Rs.2.50 per share(250%)Final Dividend |
About Zydus Lifesciences
Zydus Lifesciences FAQs
What is Share Price of Zydus Lifesciences ?
Zydus Lifesciences share price is ₹638 As on 10 December, 2023 | 02:32
What is the Market Cap of Zydus Lifesciences ?
The Market Cap of Zydus Lifesciences is ₹64634.3 Cr As on 10 December, 2023 | 02:32
What is the P/E ratio of Zydus Lifesciences ?
The P/E ratio of Zydus Lifesciences is 23 As on 10 December, 2023 | 02:32
What is the PB ratio of Zydus Lifesciences ?
The PB ratio of Zydus Lifesciences is 3.3 As on 10 December, 2023 | 02:32
What were the company's most recent reported sales and net income?
Zydus Lifesciences Ltd. recorded a net income of INR 15,265.20 crores in FY22
What is the future of the company's shares?
Zydus Lifesciences Ltd. stock is a good option for long-term investment since the shares are ripe for buying right now.
How to buy shares of Zydus Lifesciences Ltd.?
The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.